Uveitis is a common ocular immune-mediated disorder characterized by a protracted course and high recurrence rate. Corticosteroids remain the cornerstone for managing this intra-ocular inflammation. In recent years, advances in pharmaceutical technology have driven the development of novel intravitreal corticosteroid implants, particularly long-acting sustained-release formulations. These devices have been increasingly integrated into the clinical management of a broad spectrum of immune-mediated and vascular ocular diseases, among which the dexamethasone intravitreal implant and fluocinolone acetonide intravitreal implant are emerging as preferred options for non-infectious uveitis. However, standardized clinical practice guidelines or expert consensus statements regarding the use of these implants remain lacking in China. Appropriate administration of such implants enables rapid suppression of intraocular inflammation, mitigation of inflammatory tissue damage, and effective prevention of disease recurrence. Conversely, inappropriate use may lead to suboptimal therapeutic outcomes, disease reactivation, or even severe adverse events. To promote the standardized application of long-acting sustained-release intravitreal corticosteroid implants in the management of non-infectious uveitis, the the Ocular Immunology Group of the Chinese Ophthalmological Society and the Uveitis and Immunology Group of the Chinese Medical Doctor Association has formulated the present recommendations based on the best available evidence from both domestic and international clinical studies, with the aim of guiding clinicians in the rational implementation of intravitreal corticosteroid therapy.